Range Low Price High Price Comment
30 days $4.69 $7.28 Monday, 29th Apr 2024 CAPR stock ended at $5.33. This is 1.48% less than the trading day before Friday, 26th Apr 2024. During the day the stock fluctuated 7.82% from a day low at $5.27 to a day high of $5.68.
90 days $3.56 $7.28
52 weeks $2.68 $8.22

Historical Capricor Therapeutics prices

Date Open High Low Close Volume
Feb 01, 2016 $2.65 $2.89 $2.60 $2.67 7 600
Jan 29, 2016 $2.50 $2.89 $2.38 $2.67 34 900
Jan 28, 2016 $2.70 $2.70 $2.16 $2.52 36 000
Jan 27, 2016 $2.15 $2.45 $2.15 $2.33 28 900
Jan 26, 2016 $2.09 $2.26 $2.05 $2.26 7 400
Jan 25, 2016 $2.30 $2.30 $2.22 $2.28 4 500
Jan 22, 2016 $2.13 $2.36 $2.05 $2.22 25 100
Jan 21, 2016 $2.07 $2.12 $2.00 $2.12 8 000
Jan 20, 2016 $2.00 $2.14 $1.88 $2.14 47 600
Jan 19, 2016 $2.09 $2.23 $2.01 $2.03 10 900
Jan 15, 2016 $2.00 $2.12 $2.00 $2.10 6 800
Jan 14, 2016 $2.10 $2.13 $1.98 $2.01 18 400
Jan 13, 2016 $2.19 $2.36 $2.05 $2.05 26 200
Jan 12, 2016 $2.25 $2.29 $2.15 $2.16 7 800
Jan 11, 2016 $2.31 $2.37 $2.22 $2.22 12 300
Jan 08, 2016 $2.60 $2.61 $2.40 $2.42 20 400
Jan 07, 2016 $2.65 $2.65 $2.32 $2.40 31 200
Jan 06, 2016 $2.79 $3.05 $2.66 $2.66 12 400
Jan 05, 2016 $2.94 $2.98 $2.80 $2.97 12 700
Click to get the best stock tips daily for free!

About Capricor Therapeutics

Capricor Therapeutics Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Ph... CAPR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT